What happened, in summary

This anonymized patient reflected on more than 10.5 years of living with Stage IV non-small cell lung cancer. She was diagnosed in 2014 after a local clinic completed about 2 weeks of testing and told her she had Stage IV cancer. At first, her local doctor did not know the biomarkers driving the cancer and started intravenous chemotherapy. The patient felt that something more needed to be explored, so she sought care at a university health-care center. There, she learned about biomarker testing, targeted therapy, and clinical trials. The wording was imperfect, but it supported ALK-positive disease and treatment options tied to that biomarker. She emphasizes that knowing biomarkers changed what was possible for her. Earlier targeted-therapy and clinical-trial approaches did not all work, but she stayed connected with a research-focused care team. A later clinical trial, described with unclear wording, became another option after years of treatment. She said the trial was working, her tumors were shrinking, and she was in cycle 4 and heading into cycle 5. As of December 2024, she was still living with Stage IV lung cancer and speaking about clinical trials, trust in care teams, and the importance of looking for options beyond the first treatment offered.